Evaluation of new markers for minimal residual disease monitoring in B‐cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; 00B: 000–000

Abstract

CD73 and CD86 are the most relevant markers to incorporate in the routine MRD evaluation of BCPALL. © 2016 International Clinical Cytometry Society.

Prognostic impact of CD200 and CD56 expression in adult acute lymphoblastic leukemia patients

“…Higher figures (95 and 80.3%) were reported by Alapat et al [24] and Adnan Awad et al [25], respectively and it was suggested to be used as minimal residual disease markers as well as for targeted therapy. However, Tembhare et al [26] reported 28.9% among B cell precursor ALL. In our study, CD56 + positive expression was found in only 10% of cases.…”

Applications of Flow Cytometric Immunophenotyping in the Diagnosis and Posttreatment Monitoring of B and T Lymphoblastic Leukemia/Lymphoma

“…With the improvements in induction therapy for pediatric B lymphoblastic leukemia, attention is gradually shifting to later time points from therapy, End of Consolidation in particular, in order to identify patients who have had inadequate response to initial therapy and who might benefit from one of multiple novel treatments now available, for example, anti‐CD19 or anti‐CD22 therapy. To this end, new reagents have been identified that may allow improved discrimination of hematogones from residual leukemia , a few of which have been demonstrated to be of potential value in defined reagent combinations tested on patient cohorts , these include CD49f , CD81 , CD123 , CD73 (see Fig. ), CD86 , and CD304 .…”

“…To this end, new reagents have been identified that may allow improved discrimination of hematogones from residual leukemia , a few of which have been demonstrated to be of potential value in defined reagent combinations tested on patient cohorts , these include CD49f , CD81 , CD123 , CD73 (see Fig. ), CD86 , and CD304 . To date, testing of these reagents has been performed largely at diagnosis and early timepoints after therapy (up to End of Induction).…”

Efficacy and safety of a bortezomib and reduced‐intensity cytarabine‐based protocol, TMC ALLR1, for relapsed childhood ALL in India

“…Remission at extramedullary sites was evaluated by clinical assessment for testicular disease and clearance of blasts from two consecutive cerebrospinal fluid (CSF) analyses for CNS relapses. MRD was assessed by flow cytometry (FCM) (Tembhare et al , ; Gupta et al , ) and quantitative polymerase chain reaction (PCR) (van der Velden et al , ; Parker et al , ). Primary endpoint was CR2 and secondary analyses were toxicities (CTCAE 4.0 grade 3–5; https://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf) during the course of therapy.…”